China's Drugs Stocks Plunge Amid Vaccine Scandal

The transcript discusses an investigation into a Chinese vaccine company missing manufacturing records, affecting 215,000 vaccines. This has caused public panic due to the company's large market presence. Regulatory bodies face challenges in addressing the issue, despite efforts to improve quality control and increase personnel. The case is considered isolated and not indicative of the entire industry's practices.

What is the significance of the vaccine company being the second largest in China?

What steps have regulators taken in response to the vaccine quality concerns?